Neurovance Announces Agreement to be Acquired by Otsuka Pharmaceutical

March 2nd, 2017|

Otsuka Pharmaceutical to Acquire Neurovance, Inc.

March 2nd, 2017|

Neurovance Announces Appointment of Brian Goff as COO as the Company Prepares for the Next Stage of Growth and Development

December 14th, 2016|

Neurovance Announces Positive Centanafadine Phase 2b Results for Adult ADHD, and Plans for Phase 3 Trials

July 27th, 2016|

Neurovance Appoints Jeff Bailey to Chair Its Board of Directors

January 7th, 2016|

Neurovance Announces Series of Three Clinical Trials to Support Advanced Development of Centanafadine (CTN) in Adult ADHD

January 7th, 2016|

Neurovance Announces Top-Line Study Results Suggest Lower Abuse Potential for Centanafadine Compared to Stimulants Used for Adult ADHD

December 11th, 2014|

Neurovance Completes Enrollment in Human Abuse Liability Study for Centanafadine (Formerly Called EB-1020) for Adult ADHD

August 7th, 2014|

Neurovance Appoints Brigitte Robertson, MD, Vice President, Clinical Development

August 5th, 2014|

Neurovance’s Lead Product Granted Non-Proprietary Name; EB-1020 SR Now Called Centanafadine SR

June 11th, 2014|